1. Home
  2. EPAM vs CORT Comparison

EPAM vs CORT Comparison

Compare EPAM & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EPAM

EPAM Systems Inc.

HOLD

Current Price

$115.46

Market Cap

5.9B

Sector

Technology

ML Signal

HOLD

Logo Corcept Therapeutics Incorporated

CORT

Corcept Therapeutics Incorporated

N/A

Current Price

$113.95

Market Cap

9.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EPAM
CORT
Founded
1993
1998
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
9.7B
IPO Year
2011
2001

Fundamental Metrics

Financial Performance
Metric
EPAM
CORT
Price
$115.46
$113.95
Analyst Decision
Buy
Buy
Analyst Count
14
5
Target Price
$196.21
$96.50
AVG Volume (30 Days)
1.1M
710.8K
Earning Date
05-07-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
3.49
0.09
Revenue
$1,450,448,000.00
$761,407,000.00
Revenue This Year
$8.30
$26.08
Revenue Next Year
$7.17
$26.98
P/E Ratio
$33.04
$1,266.44
Revenue Growth
25.02
12.79
52 Week Low
$73.06
$28.66
52 Week High
$222.53
$126.38

Technical Indicators

Market Signals
Indicator
EPAM
CORT
Relative Strength Index (RSI) 59.94 53.75
Support Level $84.19 $77.73
Resistance Level $135.00 $124.30
Average True Range (ATR) 4.57 4.62
MACD 0.27 -1.64
Stochastic Oscillator 70.51 33.09

Price Performance

Historical Comparison
EPAM
CORT

About EPAM EPAM Systems Inc.

EPAM Systems is a global IT services firm with a focus on platform engineering, software development, and consulting services. The company used to host large engineer bases in Ukraine, Belarus, and Russia, but it now delivers from various locations across different continents. EPAM's largest market is North America, which represents approximately 60% of revenue.

About CORT Corcept Therapeutics Incorporated

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

Share on Social Networks: